NextBioMedical Co Ltd

NextBioMedical Co Ltd has a price-to-book ratio of 10.32 and a price-to-tangible-book ratio of 10.32, indicating a premium valuation relative to its book value. The company's debt-to-equity ratio is 0.16, suggesting a relatively low level of leverage. However, the company's free cash flow is negative at -2944250970.0 KRW, and its capital expenditure is -3151672460.0 KRW, indicating significant investment in operations. The current ratio of 5.38 suggests strong short-term liquidity. The company's profitability is weak, with a return on equity of -0.0065 and a return on assets of -0.0052, both negative, indicating that the company is not generating returns for its shareholders or assets. The operating income is negative at -719540990.0 KRW, and the net income is also negative at -311083510.0 KRW, reflecting poor operational performance. The gross profit margin is 70.0%, which is relatively high, but the operating margin is negative, indicating that operating expenses are outpacing gross profit. NextBioMedical Co Ltd's revenue is primarily concentrated in its core business of manufacturing and sales of medical equipment. The company's geographic exposure is primarily within Korea, as it is a Korea-based company. There is no specific information provided on revenue concentration by segment or region, but the company's operations are focused on medical equipment, which is a key segment. The company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year. The company's revenue is 16476802680.0 KRW, but the negative operating and net income suggest that growth is not translating into profitability. The company's capital expenditure is significant, which may indicate investment in future growth, but the negative free cash flow suggests that these investments are not yet generating positive returns. The company faces several risk factors, including liquidity risk due to negative free cash flow and significant capital expenditure. The risk assessment indicates a medium level of liquidity risk and a low level of dilution risk. The company's net cash is negative after subtracting total debt, which could impact its ability to meet short-term obligations. The dilution potential is low, but the company's financial performance may necessitate additional financing in the future. Recent events and filings indicate that the company is actively involved in research and development of medical equipment, which is a key area for future growth. The company's financial performance, however, is a concern, with negative operating and net income. Analyst estimates suggest a range of price targets, with a mean of 97,333.33 KRW and a median of 89,000.00 KRW, indicating some optimism about the company's future performance.